Cellseed Inc. · TSE:7776
Cellseed — H1 2022 Earnings Presentation
29 slides from Cellseed's earnings presentation, Aug 25, 2022
Slide 1: Fiscal 2022 First-Half Earnings Results Presentation
CellSeed Inc. Fiscal 2022 First-Half Earnings Results Presentation JASDAQ Growth Stock Code:7776
Slide 2: Contents
Contents Company Profile Financial Summary Second Quarter of Fiscal Year Ending December 31, 2022 Progress of each business Copyright © CellSeed Inc. All Rights Reserved. 1
Slide 3: CellSeed Inc. Corporate Information
CellSeed Inc. Corporate Information Established May, 2001 Core competence Cell Sheet Engineering based on Temperature Responsive Polymers Listed JASDAQ（7776) in 2010 Business Regenerative Medical Regenerative Medicine Products Business Supporting Business • Commercialization of Cell Sheet Therapies
Slide 4: Our Business Model
Our Business Model Mission We take the initiative of contributing to global health care in the valuable and innovative field of regenerative medicine. Medical Hospitals Seeds Products Patients Treatment University Base of Innovation Collaborative Fee Medical Research Expenses Business Alliance Partn
Slide 5: Development of Treatment Using Cell Sheet Engineering
Development of Treatment Using Cell Sheet Engineering Copyright © CellSeed Inc. All Rights Reserved. 4
Slide 6: Contents
Contents Company Profile Financial Summary Second Quarter of Fiscal Year Ending December 31, 2022 Progress of each business Copyright © CellSeed Inc. All Rights Reserved. 5
Slide 7: Half-year financial summary FY 12/2022
Half-year financial summary FY 12/2022 FY2022 Non-Consolidated FY2021 Consolidated （January 2022 - December 2022） （January 2021 - December 2021） Amount Amount （Millions of Yen） （Millions of Yen） Net sales 74 81 Operating profit -348 -466 Ordinary profit -352 -477 Net Income -357 -486 As quarterly fi
Slide 8: Completion of exercise of the 22nd share acquisition right
Completion of exercise of the 22nd share acquisition right (with the exercise price correction provision) On June 22, 2022, we completed the Exercise price 116-170 yen per share exercise of all of the 22nd share acquisition No. of share acquisition rights 44,000 rights issued on Jan. 5, 2022 with th
Slide 9: Contents
Contents Company Profile Financial Summary Second Quarter of Fiscal Year Ending December 31, 2022 Progress of each business Copyright © CellSeed Inc. All Rights Reserved. 8
Slide 10: Cell cultureware in the regenerative medicine supporting business
Cell cultureware in the regenerative medicine supporting business Professor Okano of Tokyo Women’s Medical Temperature-responsive cell cultureware 1989 University invented temperature-responsive cell cultureware. invented by Professor Okano of Tokyo 2004 Released RepCell® and HydroCell® Women's Medi
Slide 11: CellSeed Temperature Sensitive Cell Cultureware Lineup
CellSeed Temperature Sensitive Cell Cultureware Lineup UpCell® RepCell® This cultureware In addition to the same maintains the characteristics as those physiological activity of of UpCell®, this cells and retains a high cultureware allows for level of antigen proteins the recovery of cells in a on t
Slide 12: The new product UpCell to be released in Oct.
The new product UpCell® to be released in Oct. Cell Culture Insert for UpCell® Flask UpCell® 6 Well For UpCell® Flask, we plan to release products whose culture area is larger than that of the existing UpCell® Dish. It is possible to collect a larger amount of intact cells, so this is suited for r
Slide 13: Cultivation of new markets for cell cultureware
Cultivation of new markets for cell cultureware Recently, the production of bio-pharmaceutical products using mass-cultured cells, the immunotherapy using cells, and initiatives for solving food and environmental issues have been active. In the generally used cell collection technology, proteolytic
Slide 14: Head office, CPC, New development and manufacturing facility
Head office・CPC・New development and manufacturing facility Time 24 Aomi Cell Cultureware Innovation Center Time 24 Building, 4-32, Aomi 2-chome, Koto-ku, Tokyo CellSeed Haneda Airport Telecom Center Sta. Head Office 15F (East Wing) Telecom Center Building 2-5-10, Aomi, Koto-ku, Tokyo Cell Processing
Slide 15: Regenerative Medicine Supporting Business
Regenerative Medicine Supporting Business Development of Manufacturing Methods and 1 Contract Manufacturing for Cell Sheet Products Development of cell sheet manufacturing methods Contract manufacturing of cell sheet products Quality testing of cell sheets, etc. Facility Management and Applica
Slide 16: Commissioned projects in our regenerative medicine service
Commissioned projects in our regenerative medicine service For the regenerative medicine service, we obtained the permission to manufacture specific processed cells (facility No. FA3160008) in March 2017 and the permission to manufacture products for regenerative medicine in October 2018 and have un
Slide 17: Pipeline Progress
Pipeline Progress Regenerative medicine The Act on the Safety of The Act on Pharmaceuticals Regenerative Medicine and Medical Devices Self-funded Clinical Manufacturing medical research and sales treatment Fundamental Clinical Clinical trials Application Pipeline Sales research research First phase
Slide 18: Epithelial Cell Sheet for Esophageal Regeneration
Epithelial Cell Sheet for Esophageal Regeneration (CLS2702C/D) A medical treatment developed by Tokyo Women’s Medical University as a regenerative treatment for esophageal cancer (to heal esophageal wound and prevent stricture) Cell sheet is on a temperature-responsive cell culture ware and then
Slide 19: Clinical Research and Clinical Trials of Esophageal Cell Sheet
Clinical Research and Clinical Trials of Esophageal Cell Sheet Tokyo Women’s Medical University Clinical Research at Universities 2008－2014＜Japan＞ Tokyo Women’s Medical Univ. 10case Tokyo Women’s Medical Univ. Basic 10case Development and Nagasaki Univ. Agreement ＜Europe＞ Karolinska University Hos
Slide 20: Chondrocyte Sheet
Chondrocyte Sheet Disease characteristics • Causes:ageing・obesity traumatic • No treatment to regenerate lost cartilage is available In Japan, estimated number of potential patients about 30 million persons of which, about 10 million shows symptoms. Autologous chondrocyte sheets Allogeneic c
Slide 21: Acquisition of a patent regarding allogeneic cartilage cell sheets
Acquisition of a patent regarding allogeneic cartilage cell sheets In April 2022, we acquired a patent on allogeneic cartilage cell sheets we are currently developing. We had jointly applied for this patent with Professor Sato of Tokai University. Application No. 2019-165747 Patent No. 7058397
Slide 22: National Center for Child Health and Development agrees to sign a contract for supplying specimens
National Center for Child Health and Development agrees to sign a contract for supplying specimens We are now able to continuously receive cartilage cells, which are required for producing and selling allogeneic cartilage cell sheets, from National Center for Child Health and Development. After obta
Slide 23: Industry-academia collaboration in cartilage cell sheets
<Allogeneic cells> Industry-academia collaboration in cartilage cell sheets 2017 2018 2019 2020 2021 2022 2023 2024 Tokai Univ. Clinical research Follow-up to 10 cases clinical research Clinical trials for allogeneic chondrocyte cell sheets Project to Support Seeds Development AMED Submission trial
Slide 24: Process of producing allogeneic cartilage cell sheets (CLS2901C)
Process of producing allogeneic cartilage cell sheets (CLS2901C） Cell Bank An extra finger excised from a Isolated Frozen Amplified Successive Semination patient with cartilage storage culture culture polydactyly P0 P1 Cell Stock PX Working Cell Bank （Master Cell Bank） Safety Safety Safety Cell Shee
Slide 25: What we need to do before a clinical trial
What we need to do before a clinical trial Establishment of a stable system for supplying tissue for a cell bank Check of safety of tissue provided by donors Safety Check of safety of a cell bank produced from tissue • Safety test of a cell bank • Virus test for a cell bank Check of the effe
Slide 26: Test for checking the effectiveness of a cell bank
Test for checking the effectiveness of a cell bank We produced cell banks with passage number 1 and with passage number 2 from the tissue obtained from 4 donors. Then, we implanted the cell sheets produced from these cell banks to rats with cartilage damage. In the group with cell sheets implant
Slide 27: Allogeneic chondrocyte sheets
Allogeneic chondrocyte sheets 2017 Clinical Research at Tokai University | 2019 Completed in December 2019 transplants of 10 cases 2018 Adopted as the ancillary project of AMED Adopted as “a project for developing fundamental evaluation technologies for industrializing regenerative | medicine (suppo
Slide 28: Start of joint research with Hokkaido University
Start of joint research with Hokkaido University We have commenced collaborative research with Hokkaido University regarding the new therapy based on our cell sheet engineering and diseases related to the damage to the central nervous system. The central nervous system includes the brain and the spi
Slide 29: Disclaimer
This presentation is made by CellSeed Inc. solely for the disclosure of the financial statements, and not published for the purpose of soliciting sales or purchases of securities in Japan and any other regions. Copyright © CellSeed Inc. All Rights Reserved.